AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00431431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tibolone
Description: 2 years treatment with tibolone (1.25 mg Org OD-14)
Study NCT03187496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Each subject will receive rosuvastatin on Days 2 and 13.
Study NCT03187496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-305
Description: Each subject will receive EDP-305 on Days 5 through 15.
Study NCT02370459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AFIX in-person consultation
Description: The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
Study NCT02370459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AFIX webinar consultation
Description: The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
Study NCT00431431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raloxifen
Description: 2 years treatment with raloxifene (60 mg)
Study NCT00003900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00003900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT01105143 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: multimodal lifestyle intervention
Description: multimodal lifestyle intervention will be performed to reduce body weight
Study NCT01105143 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no intervention, only follow up
Study NCT00877513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Description: Smoking cessation program over 8 weeks, consisting of cognitive behavioral counseling every 2 weeks along with adjunctive use of bupropion
Study NCT01989910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Raltegravir 400mg oral twice daily
Study NCT01880255 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
Study NCT02805556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: Single oral dose of BMS-663068
Study NCT02805556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-626529
Description: Single intravenous dose of \[13C\]BMS 626529
Study NCT05006898 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PBO to control presbyopia symptoms
Description: Low dose PBO to control presbyopia symptoms
Study NCT05006898 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PBO to control presbyopia symptoms
Description: Low dose PBO to control presbyopia symptoms
Study NCT02934776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI machine
Description: The Philips Ingenia 3.0T is an MRI machine intended to be used by specialist radiologists in the hospital. It is able to acquire high quality images of wide variety of organs. For imaging the prostate, T2-weighted turbo spin-echo images are normally obtained in three orthogonal planes (axial, sagittal and coronal). This device is been clinically used in the MRI department in Belinson hospital.
Study NCT03471767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05
Description: Dextromethorphan Immediate Release + Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
Study NCT03471767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion SR
Description: Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
Study NCT01662297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine will be administered at a dosage prescribed by veterans' current providers for the treatment of insomnia.
Study NCT03447873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to DRV/cobicistat + 3TC
Description: Switch to darunavir/cobicistat + lamivudine once daily
Study NCT03537703 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Active tDCS + Auditory Training
Description: Active tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 20 min. The auditory training exercise will 20 min of computerized auditory training using the Sound Sweeps module of the Posit Science Brain HQ
Study NCT03537703 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS + Control Condition
Description: Active tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 20 min. The control condition will be subjects watching a silent movie for 20 min during active tDCS stimulation.
Study NCT03537703 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Sham tDCS + Auditory Training
Description: Sham tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 1 min with the current then slowly ramped down to 0 amps over the course of another minute. The auditory training exercise will 20 min of computerized auditory training using the Sound Sweeps module of the Posit Science Brain HQ
Study NCT01662297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: Veterans willing to switch from quetiapine to trazodone for the treatment of insomnia will receive up to 400mg of trazodone daily.
Study NCT03744780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Workshop for Emotional Eating
Description: This is a one-day intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's (2016) brief emotional eating intervention, which was derived from Forman et al.'s (2013) Mind Your Health program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness.
Study NCT01989910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Efavirenz 600mg oral at bedtime
Study NCT02191787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seresis®
Study NCT02467296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary plan with controlled amount of Sodium
Description: Dietary plan with 1.5 gr vs 3 gr of Sodium
Study NCT02191787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03154632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Therapy
Description: Ultrasound equipment will be used, choosing a continuous mode, with a frequency of 1MHz and an intensity of 1.0 W/cm2. The technique will be applied during 6 minutes with circular movements and a speed of approximately between 2.5 and 4 centimeters per second.
Study NCT03154632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Capacitive Diathermy Therapy
Description: The DCD equipment will be used choosing the musculotendinous injury FAST program which lasts 6 minutes. The applicator will move with a velocity approximately between 2.5 and 4 centimeters per second.
Study NCT02181920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole
Study NCT02181920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Study NCT02181920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac placebo
Study NCT02181920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole placebo
Study NCT01026064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: Cantharone topical liquid containing 0.7% cantharidin (blistering agent) is applied as 25 µL of 0.1% cantharone solution in acetone
Study NCT01026064 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cantharidin
Description: Cantharone topical liquid containing 0.7% cantharidin (blistering agent) is applied as 25 µL of 0.1% cantharone solution in acetone
Study NCT01026064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Zithromax (250 mg oral capsule).
Study NCT01026064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT02747732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6
Description: Therapy initiation 30 days max from screening.~Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT
Study NCT01368302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment (ABMT)
Description: Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
Study NCT01368302 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Bias Modification Treatment (ABMT)
Description: Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
Study NCT01359748 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Reference sphygmomanometer
Description: \* USED Audible Korotkoff (K5)for Auscultatory sphygmomanometer.
Study NCT02622789 — intervention group
Intervention type: OTHER
Intervention: Pilates Exercises
Description: Pilates method based stability exercise intervention
Study NCT03688971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan
Description: Omiganan Topical Gel
Study NCT03688971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: Ketoconazole Cream
Study NCT03688971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study NCT01293604 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Daily ingestion of whole grain barley and oats
Description: Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats. After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast. During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.
Study NCT01293604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily ingestion of whole grain barley and oats
Description: Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats. After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast. During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.
Study NCT01293604 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily ingestion of whole grain barley and oats
Description: Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats. After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast. During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.
Study NCT00269880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.
Study NCT00269880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.
Study NCT00269880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparin
Description: Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.
Study NCT00269880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.
Study NCT02423135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Description: Volunteers make a blood donation and after 36 days of storage this blood is re-infused in the same volunteers.
Study NCT03299816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching DASH group (C-DASH)
Description: Participants assigned to the C-DASH diet advice group will be provided $30/week worth of fruits, vegetables, nuts and beans ordered through the study coach and delivered to a community location to reach a certain goal of potassium intake (months 0-4). During phase 2 of the study (months 5-12), a study coach will continue telephonic contact with the participants to set goals for following a DASH-like diet without the weekly food allowance.
Study NCT03299816 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Shopping DASH group (S-DASH)
Description: Participants will be given a brochure containing information about the DASH diet which will be reviewed with a study team member. In months 1-4, participants will receive a gift card equivalent to a weekly allowance of $30 to Klein's ShopRite stores of Maryland for purchases of food and beverages of their choice. During phase two (months 5-12), they will be asked to continue following a DASH-like diet but will not receive a gift card for purchases.
Study NCT02311907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV, over 30 minutes per planned chemotherapy regimen
Study NCT02311907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Given IV, over 30 minutes per planned chemotherapy regimen
Study NCT02311907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: Given IV, over 15 minutes, immediately before chemotherapy administration
Study NCT02311907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02311907 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02311907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV, over 1 or 3 hours, per planned chemotherapy regimen
Study NCT02311907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Given IV, over 1 or 3 hours, per planned chemotherapy regimen
Study NCT02311907 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IV
Study NCT02311907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02311907 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00109785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Study NCT00109785 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Study NCT00109785 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 124 iododeoxyuridine
Study NCT00835380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine, Purified Inactivated (VAQTA™)
Description: Subjects will be given a 25-U/0.5 mL intramuscular injections of VAQTA™ at Day 1 and Month 6.
Study NCT01953757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegan diet and vitamin B12 supplement
Description: A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
Study NCT01953757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 supplement
Description: A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
Study NCT03411239 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Adult esophageal balloon catheter (obc)
Description: Using OBC to determine airway pressure changes in patients undergoing general anaesthesia for laparoscopic surgery
Study NCT02950558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Single injection of ropivacaine immediately prior to surgery.
Study NCT02950558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Single injection of ropivacaine immediately prior to surgery.
Study NCT02950558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve block
Description: insertion of catheter to deliver continuous 5 day popliteal sciatic nerve block using a disposable ambulatory pain pump.
Study NCT00288691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil (BAY86-5294)
Description: 5mg/day
Study NCT00288691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil (BAY86-5294)
Description: 10mg/day
Study NCT00288691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil (BAY86-5294)
Description: 25mg/day
Study NCT00288691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02892162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional LAAW linear ablation
Description: Additional linear ablation on LAAW using ThermoCool SmartTouch ablation catheter.
Study NCT02892162 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Additional LAAW linear ablation
Description: Additional linear ablation on LAAW using ThermoCool SmartTouch ablation catheter.
Study NCT03385967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Addition of Dexmedetomidine in block .25mcg/kg of dexmedetomidine
Study NCT03385967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: Standard of care 0.5%ropivacaine
Study NCT00920725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin (Aspart Insulin [Novolog], Regular Insulin)
Description: Aspart Insulin 0.2units/sq q 2 hours~Regular Insulin 0.1units/kg/hr intravenous~Aspart Insulin 0.1 units/kg/hr intravenous
Study NCT01229358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical dressing
Description: Acticoat Absorbant™ vs standard dry gauze as the immediate post operative dressing
Study NCT01229358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical dressing
Description: Acticoat Absorbant™ vs standard dry gauze as the immediate post operative dressing
Study NCT01414842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated sodium profiling in endogenous hemodiafiltration
Description: Automated sodium profiling during endogenous reinfusion hemodiafiltration technique. The device processes the dialysate sodium and ultrafiltration rate during dialysis to achieve a preset sodium target at the end of the treatment. Sodium dialysate and maximal ultrafiltration rate are constraint within safety limits during dialysis.
Study NCT01414842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard sodium dialysate
Description: Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
Study NCT01359748 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sphygmomanometer under test
Description: Electronic Oscillometric method.
Study NCT01593969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUTF/Flax Oil
Description: Ready to Use Therapeutic Food
Study NCT01593969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUTF/Flax Oil plus additional Fish Oil
Description: Ready to Use Therapeutic Food